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Signal transductionMitochondria, cellular powerhouses of eukaryotes, are known to act as central hubs for multiple signal transduc-
tions. Recent research reveals that mitochondria are involved in cellular innate antiviral immunity in vertebrates,
particularly mammals. Mitochondrial-mediated antiviral immunity depends on the activation of the retinoic acid-
inducible gene I (RIG-I)-like receptors signal transduction pathway and on the participation of a mitochondrial
outer membrane adaptor protein, called the “mitochondrial antiviral signaling (MAVS)”. In this review, we discuss
unexpected discoveries that are revealing how the organelles contribute to the innate immune response against
RNA viruses. This article is part of a Special Issue entitled: Mitochondrial dynamics and physiology.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria, which are compartmentalized by two membrane
bilayers (outer and inner membranes), are well known to be involved
in a wide variety of functions in eukaryotic cells. They are featured on
unique organelles not only by their double-membrane structure but
also because they contain their own genome; an approximately 16 ki-
lobase circular mitochondrial DNA (mtDNA) encodes 13 protein
genes, which are essential for the respiratory function of mitochon-
dria to generate adenosine triphosphate (ATP) [1].
Serving as cellular powerhouses by virtue of their aerobic respiration,
mitochondria also participate in numerous crucial cellular processes, in-
cluding calcium homeostasis [2–4], apoptosis [5,6], multiple cell signaling
[7–10], and aging [11,12]. Within the past decade, one of the most im-
pressive discoveries regarding the novel functions of mitochondria is
their mission in cellular innate antiviral immunity in vertebrates, partic-
ularly mammals [13–18]. Because mitochondria are believed to have
evolved from organisms such asα-proteobacterium, their newly discov-
ered role of branching into the host-cell defense was unexpected. In this
review, we discuss recent insights into the fundamental phenomenon of
mitochondrial involvement in cellular innate antiviral immunity.
2. Cellular innate immune response against RNA viruses
Innate immunity is an essential and ubiquitous system that defends
organisms from infectious pathogens. The innate immune response isMitochondrial dynamics and
rights reserved.typically triggered by the recognition of broadly conserved microbial
components known as pathogen-associated molecular patterns
(PAMPs), including lipopolysaccharide (LPS) of Gram-negative bacteria,
β-1,3-glucans of fungi, peptidoglycans of Gram-positive bacteria, and
genetic materials (DNA or RNA) of viruses [19–21]. The recognition of
PAMPs by germline-encoded pattern recognition receptors (PRRs) ulti-
mately activates intracellular signaling cascades that result in transcrip-
tional activation, and ﬁnally leads to the clearance and killing of
infectious microbes [20,21].
RNA viral infection of host cells is sensed by PRR recognition of a
PAMP such as double-stranded RNA (dsRNA), that initiated two distinct
signaling pathways [21–23]. The ﬁrst pathway is known to be mediated
by Toll-like receptor 3 (TLR-3). Endosomal expressing TLR-3 recognizes
virus-derived dsRNA that gains entry into the host cell through endocy-
tosis (Fig. 1). The second pathway is prompted by either of the two reti-
noic acid-inducible gene I (RIG-I)-like receptors (RLRs), RIG-I and
melanoma differentiation-associated gene 5 (MDA-5), each ofwhich de-
tects cytoplasmic viral dsRNA [24–27]. Although TLR-3 and RLR path-
ways differ with respect to their initiating stimuli and downstream
effectors, they converge at the point of the activation of the transcrip-
tional factors, nuclear factor κB (NF-κB) and interferon regulatory factor
3 (IRF-3), resulting in the rapid production of type I interferons (IFN-α
and -β) and other proinﬂammatory cytokines that promote the subse-
quent development of adaptive antiviral immunity [23,28,29].
At almost the same time in 2005, four independent labs found an
adaptormolecule acting just downstream from RIG-I/MDA-5, mitochon-
drial antiviral signaling (MAVS) [13] (also called interferon-β promoter
stimulator 1 (IPS-1) [30], CARD adaptor inducing IFN-β (Cardif) [31],
and virus-induced signaling adaptor (VISA) [32]). In these studies,
Chen and colleagues have revealed that MAVS is located at the mito-
chondrial outer membrane, and that its proper localization to the
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reports have clearly shown that MAVS cellular deﬁciency, generated ei-
ther in knockout mice [33,34] or by the cleavage of virus proteases
(NS3/4A and 3ABC) [31,35,36] or caspases [37], abolishes the production
of type I IFNs and inﬂammatory cytokines, underscoring the importance
of the link between antiviral innate immunity and mitochondria.
3. Mitochondrial antiviral signaling (MAVS)
MAVS, comprising 540 amino acids in Homo sapiens, is a mito-
chondrial integral outer-membrane protein with a predicted molecu-
lar mass of 56 kD (Fig. 2A), although it is assembled to form a
supramolecular complex (approximately 600 kD) under physiologi-
cal conditions [38]. MAVS is encoded in the nuclear genome (not in
mtDNA) and is expressed ubiquitously in a variety of tissues and
cell types [13,31,32]. So far, it has been reported that some MAVS
orthologs are conserved throughout ﬁsh species [39–41] (Fig. 2B).
In its structure, MAVS contains an amino terminal caspase activation
and recruitment domain (CARD) comprising six helices; three (H1a, H3,
andH4) that form a ﬂat positively charged surface and two (H2 andH6)
that form an acidic negatively charged surface on the opposite side [42]
(Fig. 2A). The RLRs (RIG-I and MDA-5), upstream molecules of MAVS,Fig. 1. Overview of innate immunity against RNA viruses in mammals. Viral infections of
stranded RNA (dsRNA), which initiates two distinct signaling pathways (TLR-3 and RLR). A
stream effectors, they converge at the point of transcriptional activation (NF-κB or IRF-3/7)
Mitochondrial-mediated antiviral immunity depends on the activation of the RLR signalingalso contain tandem CARDs at their N-terminals [24,27] that interact
with the CARD of MAVS, resulting in the activation of intracellular sig-
naling cascades. At the carboxy terminal region, MAVS contains a single
spanning-transmembrane (TM) domain (Fig. 2B) that is responsible for
proper mitochondrial localization [13] and its self-association through
the stacking of aromatic residues [43]. These properties of MAVS (i.e.,
mitochondrial localization, oligomerization, and possession of the
CARD domain) seem to be the minimal requirements for its cellular
function, because overexpression of a MAVS mutant containing only
the CARD and TM domains (called mini-MAVS) is sufﬁcient to induce
signal transduction [13,35].
However, several lines of study have implicated that the subcellular
localization of MAVS is not only on the outer mitochondrial membrane.
As well as mitochondrial ﬁssion 1 (Fis-1) andmitochondrial ﬁssion fac-
tor (Mff), both ofwhich are known to co-exist inmitochondria and per-
oxisomes [44,45], Kagan and colleagues demonstrated that MAVS also
exists on the membranes of peroxisome, a metabolic organelle, and
that the peroxisomal MAVS is involved in the early induction of IFN-
stimulated genes such as viperin, before mitochondrial MAVS induces
a sustained antiviral response [46]. In addition to this peroxisomal dis-
tribution, another group found MAVS in mitochondrial-associated en-
doplasmic reticulum membranes (MAM) [47]. Although the multi-mammalian host cells are detected by the cells' recognition of virus-derived double-
lthough these two pathways differ with respect to their initiating stimuli and down-
, resulting in the rapid production of type I interferons and proinﬂammatory cytokines.
pathway.
Fig. 2. MAVS domain structure and its sequential alignment among different species. (A). A schematic representation of human MAVS, showing the locations of the CARD domain
(CARD), the proline-rich region (PRR), and the transmembrane segment (TM). The amino acid positions are indicated below the structure. The crystal structure of the CARD domain
[42] is inserted into the ﬁgure. The basic amino acids are colored in blue and the acidic residues are in red. The hepatitis C virus (HCV) serine protease, NS3/4A, cleavage site (Cys508)
is located just upstream from TM. (B). Sequential alignment of the CARD, PRR, and TM among different species of MAVS using the Clustal W program. The asterisk (*) indicates the
conserved residues among these species, and the colon (:) indicates the residues that have similar properties.
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organelles are interconnected and interdependent in cellular
metabolism.
Aside from its CARD and TM domains, MAVS contains another
functional domain (Fig. 2A and B); a proline-rich region (PRR) that
is involved in downstream signaling via its interaction with the
tumor necrosis factor receptor-associated factor (TRAF) family, in-
cluding TRAF2, TRAF3, and TRAF6 [32,48] (described in the next sec-
tion). It remains unclear, however, why a MAVS mutant lacking the
PRR retains its signaling capacity [13,35].
4. Activation of MAVS signalosome
Upon RNA viral infection, the RNA helicases (RIG-I and MDA-5)
recognize virus-derived RNA ligands, leading to auto-activation by
its drastic conformational changes [27,49], and they translocate at
the outer mitochondrial membrane to interact with MAVS (Fig. 1).
What is the machinery that activates MAVS after the association
with RLRs, and how is that machinery regulated? Because these pro-
cesses are transient populated states during the signaling event, it has
been difﬁcult to determine the structure of MAVS directly. A
ﬂuorescence-based assay, however, provided important insight into
its structural features. Lamarre and colleagues revealed that MAVS di-
merization through its TM domain is essential for activating NF-κB
and IRF-3, and they proposed a model in which RIG-I-MAVS interac-
tion induces the MAVS dimers [43]. Indeed, Wang and colleague
have observed that RIG-I recruitment to MAVS enhances the self-
association of MAVS as analyzed by ﬂuorescence resonance energytransfer (FRET) assay, and that the formation of MAVS homodimers
would lead to the binding and activation of TRAF3, a downstream
molecule of MAVS [50].
It was revealed that, during the activation of MAVS, a scaffold pro-
tein, via its dimer formation, MAVS recruits various downstream ef-
fectors to form a signaling supramolecular assembly, a “MAVS
signalosome” which leads to the upregulation of the NF-κB and IRF-
3 pathways (Fig. 3). Many studies have identiﬁed adaptors interacting
with MAVS, and we describe a couple of examples. TRAF family mem-
bers, TRAF2, 3, and 6, are known to bind TRAF-interaction motifs
(TIM) in the PRR of MAVS [32,48] (Fig. 3; see Positive regulation).
TRAF5 has also been shown to associate with MAVS after the activa-
tion of the scaffold protein [51]. Another cast of the positive regula-
tors is tumor necrosis factor receptor-associated death domain
(TRADD). TRADD also interacts with MAVS and orchestrates the
TRADDosome complex, including TRAF3, TRAF family member-
associated NF-κB activator (TANK), Fas-associated death domain
(FADD), and receptor interacting protein 1 (RIP1); this orchestration
leads to the activation of NF-κB and IRF-3 [52]. Translocase of outer
membrane 70 (TOM70) has been identiﬁed a component of MAVS
signalosome, and is bridging TANK-binding kinase 1 (TBK-1)/IRF-3
to mitochondria [53].
Finally, we should note that the stimulator of interferon genes
(STING) [54], (an ER-integrated membrane protein that is also called
the mediator of IRF-3 activation (MITA) [55], endoplasmic reticulum
interferon stimulator (ERIS) [56], and MPYS [57]), also interacts
with MAVS (positioned downstream from MAVS) and can activate
both NF-κB and IRF-3 pathways [54,55]. As we mentioned earlier
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ther highlight the importance of the interconnectedness and interde-
pendence of mitochondria and ER in antiviral innate immunity.
5. Negative regulators of MAVS signaling
Given that the prominent function of the MAVS signalosome is
precisely regulated upon viral infection, it is most likely that the scaf-
fold protein is subjected to control in a quiescent state by negative
regulators in non-infected environments. Indeed, we have shown
that MAVS forms a stable higher-order complex (~600 kD) on the
outer membrane of mitochondria at their resting state [38].
So far, several negative regulators of MAVS, through its binding
and/or post-translational modiﬁcations, have been investigated
(Fig. 3; see Negative regulation). For instance, NLRX1 (also known
as NOD9), a novel nucleotide oligomerization domain (NOD)-like re-
ceptors (NLRs), is a ubiquitously expressedmitochondrial protein (lo-
cated at the outer membrane) that inhibits CARD-CARD interactions
between RLRs and MAVS, thereby preventing downstream signalFig. 3. Positive and negative regulations of MAVS-mediated antiviral signaling. Viral infectio
dria, and RLRs associate with MAVS via a CARD–CARD interaction (Positive regulation). MAV
recruiting various downstream effectors to form signaling supramolecular assembly (MAVS
MAVS depend on having normal mitochondrial membrane potential (ΔΨm) from healthy m
ing pathway, and increasing mROS induces the positive regulation of MAVS signaling. On th
ulators under a non-infected environment, or MAVS is promptly terminated after the antivtransduction [58,59]. However, a thorough biochemical study
revealed that NLRX1 localizes to the mitochondrial matrix [60], and
the same group found that its overexpression induced reactive oxy-
gen species (ROS), resulting in ampliﬁed NF-κB and JUN N-terminal
kinase (JNK)-dependent signaling in response to Shigella infection
[61]. At present, it is still unclear how exactly NLRX1 inhibits MAVS
if that distributes at the matrix side, so further analysis will be need-
ed. A receptor for the globular head domain of complement C1q
(gC1qR) is also translocated to the mitochondrial outer membrane
and binds with MAVS, resulting in the suppression of antiviral im-
mune responses [62].
Some RNA viruses encode protease genes not only to generate
their mature proteins required for viral replication, but also because
these genes have the potential to suppress antiviral immunity by
cleaving putative cellular targets as an evasion strategy. An example
of this is the hepatitis C virus (HCV) serine protease, NS3/4A, which
cleaves MAVS at the position of 508 (cysteine residue) (Fig. 2A) to ul-
timately abolish the RLR signaling pathway [31,35]. The hepatitis A
virus takes a similar strategy using its 3ABC cysteine protease,n can activate RLRs (RIG-I and MDA-5), leading to their translocation to the mitochon-
S activation is then triggered by its self-associations. These associations are allowed by
signalosome), which in turn leads to the activation of NF-κB and IRF-3. The functions of
itochondria. Mitochondrial ROS (mROS) acts as a second messenger for the RLR signal-
e other hand, MAVS is subjected to control in a quiescent state by several negative reg-
iral response (Negative regulation).
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of the mechanisms of MAVS inhibition are believed to disrupt the mi-
tochondrial targeting of the adaptor protein (Fig. 3). Further, hepatitis
B virus X protein (HBX) interacts with MAVS, promoting MAVS ubi-
quitination; this triggers proteasome-mediated degradation, result-
ing in the downregulation of the signaling system [63].
On the other hand, poly(rC) binding protein 2 (PCBP2) was
reported to act as a negative regulator of MAVS-mediated antiviral
signaling by leading MAVS proteasomal degradation via K48-linked
polyubiquitination [64]. PCBP2, which induces post-viral infection
into the host cells, recruits atrophin-1-interacting protein 4 (AIP4),
an E3 ubiquitin ligase, to form a tertiary complex with MAVS, and
catalyzes the K48-linked conjugation and degradation of MAVS. As
is the case with PCBP2, PSMA7, the α4 subunit of 20S proteasome,
negatively regulates antiviral signaling through proteasome-
dependent degradation of MAVS, although the details of the mech-
anism are unclear [65]. These studies provide us with a mechanism
by which MAVS signaling is promptly terminated once an antiviral
response occurs.
Finally, Polo-like kinase 1 (PLK1) inhibits the MAVS-mediated IFN-
β induction by arresting TIM in the C-terminal region of MAVS, there-
by disrupting the interaction between MAVS and TRAF3 [66]. In addi-
tion to these negative regulators, Mitofusin 2 (Mfn2), a mediator of
mitochondrial fusion, is also involved in the RLR pathway [38], as
we describe in the following section.Fig. 4. Mitochondria are dynamic organelles. (A). A schematic representation of mito-
chondrial dynamics in mammalian cells. Mitochondria are dynamic organelles that un-
dergo continuous cycles of fusion and ﬁssion. Molecules involved in mitochondrial
fusion and ﬁssion are indicated. (B). Mitochondrial morphology in wild-type (left) or
MAVS-deﬁcient (right) mouse embryonic ﬁbroblasts (MEFs). Mitochondria are visual-
ized by staining with a monoclonal antibody against mtHsp70 (red). Scale bar, 10 μm.6. Mitochondrial dynamics and antiviral immunity
In many cell types, mitochondria have a tubular morphology and
undergo continuous cycles of homotypic fusion and ﬁssion, opposing
processes that control organelle shape, copy number, and mtDNA
maintenance [67–69] (Fig. 4A). Moreover, mitochondrial dynamics
play an important role in apoptosis, a fundamental function of mito-
chondria [70,71]. In mammals, mitochondrial dynamics are con-
trolled by several mitochondrial proteins, including four high-
molecular-weight GTPases: mitofusins 1 and 2 (Mfn1 and Mfn2)
and optic atrophy 1 (OPA1) regulate fusion processes, whereas
dynamin-related protein 1 (Drp1) is involved in mitochondrial ﬁssion
[67–69] (Fig. 4A). Within the past several years, a couple of studies
have shed light on the connection between mitochondrial dynamics
and antiviral innate immunity.
The ﬁrst evidence of the role of mitochondrial dynamics in anti-
viral immunity was the discovery that Mfn2, which mediates mito-
chondrial fusion, inhibits the RLR pathway through its MAVS-
binding via a central 4,3 hydrophobic heptad region (HR1) of Mfn2
[38] (Fig. 3; see Negative regulation). In the study, we showed that
an increased abundance of Mfn2 sequesters MAVS in a nonproductive
state, thereby preventing the propagation of a downstream antiviral
response, reducing or obliterating both IFN-β expression and IRF-3
dimerization. In contrast, the loss of endogenous Mfn2 enhances the
virus-induced production of IFN-β and thereby decreases viral repli-
cation. Interestingly, we did not observe this inhibitory phenotype
with the Mfn2 homolog protein, Mfn1, despite 60% sequence identity
[38]. More recently, we found that the Mfn2-mediated inhibition of
MAVS signaling is caused by the interference with MAVS–MAVS olig-
omerization (unpublished results).
Adding to the story of the connection between innate immunity
and mitochondrial dynamics, Arnoult and colleagues reported that
activation of the RLR pathway via the defective Sendai virus (SeV)
strain H4 induces mitochondrial elongation [72]. They also demon-
strated that the knockdown of either Mfn1 or OPA1, which blocks mi-
tochondrial fusion, decreases virus-induced activation of the
transcription factors, NF-κB and IRF-3, whereas knockdown of Drp1
or Fis-1, which depletes mitochondrial ﬁssion, increases RLR signal-
ing. Importantly, they mentioned that mitochondrial dynamicswould facilitate MAVS downstream signaling by mitochondria-ER
tethering, which is involved in MAVS-STING interaction [72].
Another study reported that viral infection in the host cell triggers
MAVS re-distribution on the outer mitochondrial membrane, and this
translocation is regulated by Mfn1 because the knockdown of the
gene abolishes this rearrangement [73]. Furthermore, those authors
proposed a model of viral entrapment by mitochondria via an RIG-I-
MAVS complex [73]. Regarding MAVS re-distribution on mitochon-
dria, Chen and colleagues recently provided interesting evidence
from an in vitro study that viral infection induces the formation of
prion-like MAVS aggregates that would potentiate the activation of
IRF-3 or recruit TRAF family members, TRAF2 and 6 [74]. In this
model, they proposed that RIG-I-MAVS interaction induces rapidly
formation of MAVS functional aggregates, and that progressively con-
verts other endogenous MAVS into prion-like aggregates (a hallmark
of prion) on the outer membrane of mitochondria. However, it is still
unclear whether the aggregates accumulate under physiological con-
ditions, and how cells reform/regenerate these abnormal mitochon-
dria. Therefore much more work is required to understand the
linkage of mitochondrial dynamics to MAVS signaling.7. Mitochondrial functions and antiviral immunity
According to the studies mentioned in the section above, it is ob-
vious that mitochondrial morphology is considerably involved in
the MAVS-mediated antiviral signaling pathway. However, further
evidence implies that classical mitochondrial functions, such as mito-
chondrial membrane potential (Δψm) and mitochondrial reactive ox-
ygen species (mROS), also play key roles in innate antiviral immunity.
In fact, the mitochondria in mouse embryonic ﬁbroblasts (MEFs) with
null mutation in MAVS (MAVS−/−MEFs) still exhibit a normal and/or
more extended tubular morphology (Fig. 4B). This casts doubt upon
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thus discuss a couple of convincing studies of the mitochondrial func-
tions governing cellular antiviral signaling pathways (Fig. 3).
Mfns-deﬁcient MEFs (both Mfn1−/− and Mfn2−/−) show no de-
tectable mitochondrial fusion and have completely fragmented mito-
chondria [75,76]. Moreover, the cells display impaired induction of
type I IFNs and other proinﬂammatory cytokines in response to viral
infection [77]. Chan and colleagues have reported that the vast major-
ity of Mfns-null cells show widespread heterogeneity of Δψm, a phys-
iologic function of mitochondria [76]. Indeed, treatment of wild-type
cells with CCCP, a protonophore that dissipates Δψm, remarkably sup-
presses the antiviral immune responses [77]. In this work, we also
showed that in cells overexpressing uncoupling protein-2, which lo-
calizes the mitochondrial inner membrane and induces mitochondri-
al proton leakage [78], the extent of Δψm dissipation correlated with
the defect in RLR-induced antiviral responses [77]. Further, it is inter-
esting to note that mice lacking UCP-2were reportedly resistant to in-
fection by Toxoplasma gondii, a protozoan parasite that causes
toxoplasmosis, a result of the increased mROS generation; in contrast,
such infection is lethal for the wild-type littermates [79]. Future study
to evaluate the role of UCP-2 in a viral infection in vivo model may
prove interesting.
Mitochondrial ROS, which is generated through mitochondrial
respiration, are reportedly involved in the RLR signaling pathway.
Using autophagy-defective Atg5−/− cells, Iwasaki and colleagues
demonstrated that the accumulation of dysfunctional mitochondria,
which is responsible for increasing mROS levels, enhances RLR signal-
ing [80]. They also showed that cells treated with an antioxidant com-
pound signiﬁcantly reduced type I IFN levels, whereas rotenone
potently increased RLR signaling. In agreement with these ﬁndings,
another group reported that cellular ROS is essential for RIG-I-
mediated IRF-3 phosphorylation and dimerization, the hallmarks of
IRF-3 activation [81]. As we mentioned above, UCP-2 has potential
role in Δψm regulation, and that function is coupled with the attenu-
ation of mROS production [78,79,82]. Therefore, we can also interpret
the results to mean that the abundance of UCP-2 leads to the inactiva-
tion of MAVS-dependent signaling as the byproduct of mROS-
decreasing effect [77].
Finally, a recent paper from Levine and colleagues have revealed that
SMURF1, an E3 ubiquitin–protein ligase, acts as a newlymediator in both
viral autophagy (Sindbis and herpes simplex viruses) and mitochondrial
selective autophagy (mitophagy), uniquely linking between cellular anti-
viral response and mitochondria [83]. Collectively, these works provide a
framework for understanding how the physiologic functions of mito-
chondria are coupled with its functions in antiviral immunity.
8. Concluding remarks
Mitochondria are well known as the powerhouses of eukaryotic
cells. Recent studies indicate that mitochondria also act as a platform
for the ﬁrst line of antiviral defense. In this review, we described the
role of mitochondria only in innate immunity against RNA viruses,
but the involvement of this double-membraned organelle in immune
responses is also important for a broad range of immune responses
against other types of inﬂammation, such as bacterial infection
[84–86], sterile inﬂammation [87–89], and lymphocyte trafﬁcking
[90]. Furthermore, it is quite interesting to study the evolutional
path of this organelle, in light of the fact that innate immune re-
sponses can also be triggered by mitochondrial materials [i.e.,
mtDNA and mitochondrial N-formyl peptides (mtDNA-encoded pro-
teins translated with N-formyl methionine residue)] that leak from
damaged mitochondria [91,92]. Thus, there is no doubt that mito-
chondria have key roles in immunity, but further studies are needed
to elucidate the basic physiology of mitochondria and how the organ-
elle achieves both cellular metabolism and host defense. Finally, dys-
function of mitochondrial dynamics is also known to be implicated inneurodegenerative diseases, so it will be important to clarify the link
between mitochondrial-mediated immunity and neuropathy.
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The following abbreviations are used in the text.
AIP4: atrophin-1-interacting protein 4
CARD: caspase activation and recruitment domain
CCCP: carbonyl cyanide m-chlorophenylhydrazonedsRNA: double-stranded RNA
FADD: Fas-associated death domain
gC1qR: receptor for globular head domain of complement C1q
HBX: hepatitis B virus X protein
HCV: hepatitis C virus
IFN: interferon
IKK: inhibitor of NF-κB (IκB) kinase
IRF-3: interferon regulatory factor 3
MAVS: mitochondrial antiviral signaling
MDA-5: melanoma differentiation-associated gene 5
MEF: mouse embryonic ﬁbroblast
Mfns: mitofusins
mROS: mitochondrial reactive oxygen species (ROS)
mtDNA: mitochondrial DNA
NF-κB: nuclear factor κB
NLRX1: NOD-like receptor family member X1
PAMP: pathogen-associated molecular pattern
PCBP2: poly(rC) binding protein 2
PLK1: Polo-like kinase 1
PRR: proline-rich region
Δψm: mitochondrial membrane potential
RIG-I: retinoic acid-inducible gene I
RIP1: receptor interacting protein 1
RLR: RIG-I-like receptor
STING: stimulator of interferon genes
TANK: TRAF family member-associated NF-κB activator
TIM: TRAF-interaction motif
TLR-3: Toll-like receptor 3
TOM: translocase of outer membrane
TRADD: TNF receptor-associated death domain
TRAF: tumor necrosis factor (TNF) receptor-associated factor
UCP-2: uncoupling protein 2
